Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Preferred Stock Liabilities: 2016-2025

Historic Preferred Stock Liabilities for Rhythm Pharmaceuticals (RYTM) over the last 2 years, with Sep 2025 value amounting to $146.9 million.

  • Rhythm Pharmaceuticals' Preferred Stock Liabilities rose 3.81% to $146.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $146.9 million, marking a year-over-year increase of 3.81%. This contributed to the annual value of $142.8 million for FY2024, which is N/A change from last year.
  • Rhythm Pharmaceuticals' Preferred Stock Liabilities amounted to $146.9 million in Q3 2025, which was up 0.95% from $145.5 million recorded in Q2 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Preferred Stock Liabilities peaked at $146.9 million during Q3 2025, and registered a low of $140.2 million during Q2 2024.
  • In the last 2 years, Rhythm Pharmaceuticals' Preferred Stock Liabilities had a median value of $143.5 million in 2024 and averaged $143.5 million.
  • Data for Rhythm Pharmaceuticals' Preferred Stock Liabilities shows a peak YoY rose of 3.81% (in 2025) over the last 5 years.
  • Rhythm Pharmaceuticals' Preferred Stock Liabilities (Quarterly) stood at $142.8 million in 2024, then grew by 3.81% to $146.9 million in 2025.
  • Its Preferred Stock Liabilities stands at $146.9 million for Q3 2025, versus $145.5 million for Q2 2025 and $144.1 million for Q1 2025.